symptomatic carotid stenosis was associated with lower risk of stroke or death (3.0% vs 4.3%; RR 0.69 [95%CI 0.47-0.998]; P = .048), whereas there were no statistically significant differences in stroke or death with protamine use in asymptomatic patients (1.6% vs 1.0%; RR 1.63 [95%CI 0.67-3.92]; P = .28). Conclusions Heparin-reversal with protamine following transfemoral carotid artery stenting is not associated with an increased risk of thromboembolic events and its use in symptomatic carotid disease is associated with a lower risk of stroke or death.Objective Financial relationships between vascular surgeons (VS) and industry are essential to the development and adoption of innovative technology. However, these relationships may establish competing interests. Our objective was to describe publicly available financial transactions between industry and academic VS. Methods Academic VS were identified and characterized based on publicly available data correlated with Accreditation Council for Graduate Medical Education (ACGME) and Association of American Medical Colleges (AAMC) data to identify academic practice settings. VS were linked to Open Payments data for 2017 as reported by the Centers for Medicare and Medicaid Services (CMS). Univariate and nonparametric tests were used for analysis. Results Of 1,158 academic VS identified, 997 (86%) received industry payments totaling $8,548,034. Overall, the median of total payments received was $814 [IQR $124 - $2,863]. The top paid decile of VS received $29,645 [IQR $16,128 - $61,701]. Payments to the top decil The 3 top entities paid a total of $5,004,061 which accounted for 59% of all payments. Payments from at least one of the top 3 entities reached 76% of VS. Conclusion Most academic VS receive publicly reported industry payments which are paid by a limited number of entities, typically for food and beverage or travel and lodging. The top 10% of VS received higher median payment amounts, totaling 81% of all industry payments. VS should be aware of publicly reported payment information and the potential for conflicts of interest.Recent human genetic studies have challenged long standing hypotheses about the chain of events in Alzheimer's disease (AD), as the identification of genetic risk factors in microglial genes supports a causative role for microglia in the disease. Parallel transcriptome and histology studies at the single-cell level revealed a rich palette of microglial states affected by disease status and genetic risk factors. Taken together, those findings support microglia dysfunction as a central mechanism in AD etiology and thus the therapeutic potential of modulating microglial activity for AD treatment. SCH-527123 clinical trial Here we review how human genetic studies discovered microglial AD risk genes, such as TREM2, CD33, MS4A and APOE, and how experimental studies are beginning to decipher the cellular functions of some of these genes. Our review also focuses on recent transcriptomic studies of human microglia from postmortem tissue to critically assess areas of similarity and dissimilarity between human and mouse models currently in use in order to better understand the biology of innate immunity in AD.Background Previous studies found that Vitamin E (VE) could recruit protein kinase B (Akt1) to the membrane by targeting its unconventional lipid-binding site, which led to the dephosphorylation of Akt1 at Ser473, eventually deactivating the enzyme. Methods A series of VE-like compounds with varying types and lengths of the linker groups are designed to study the VE-driven membrane recruitment of Akt1 using a combined molecular docking and molecular dynamics (MD) simulation approach. Results We find that the linker groups with only one methylene linker and multiple hydrogen bond donors are optimal for achieving a balance between binding to the protein and partitioning into the membrane to form a stable protein-ligand-membrane ternary complex. These polar linkers are found to form stable hydrogen bonds with the lipid head groups during the MD simulations, which turns out critical for ensuring that the chromanol ring of the VE-like compounds resides above the membrane surface to fully engage in the protein. Conclusions Our results reveal the molecular determinants of the linker groups for VE derivatives' ability to anchor Akt1 to the membrane. General significance These findings will facilitate the design of membrane interfacial compounds to recruit specific proteins to the membrane to modulate the protein function.Background The goal of therapeutic drug monitoring is to determine the appropriate exposure of difficult-to-manage medications to optimize the clinical outcomes in patients under various clinical situations. Concerning antifungal treatment, and knowing that this procedure is expensive and time consuming, it is particularly recommended for certain systemic antifungals, i.e., agents with a well-defined exposure-response relationship and unpredictable pharmacokinetic profile or narrow therapeutic index. Little evidence supports the routine use of therapeutic drug monitoring for polyenes (amphotericin B), echinocandins, fluconazole or new azoles such as isavuconazole, despite the fact that a better understanding of antifungal exposure may lead to a better response. Objectives The aim of this work is to review published pharmacokinetic/pharmacodynamic data on systemically administered antifungals focusing on those whose monitoring is not routinely recommended by experts. Sources A MEDLINE search of the literature holds that can minimise the development of antifungal resistance. Implications General therapeutic drug monitoring for all systemic antifungals is not recommended, however, this approach may help to stablish an adequate antifungal exposure for a favourable response, prevention of toxicity or development of resistance in special clinical circumstances.Objective It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. Methods In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. Results The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.